Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
December 12, 2024 10:15 ET
|
Aptose Biosciences, Inc.
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells
UPDATE - Remedy Plan Therapeutics Showcases Preclinical Data from First-In-Class NAMPT Inhibitor, RPT1G, Demonstrating Synergy with BCL-2 Family Inhibitors in AML at the 2024 ASH Annual Meeting
December 10, 2024 14:10 ET
|
Remedy Plan Therapeutics
Remedy Plan Therapeutics Showcases at 2024 ASH Annual Meeting, Synergy Between RPT1G and Venetoclax
Remedy Plan Therapeutics Showcases Preclinical Data from First-In-Class NAMPT Inhibitor, RPT1G, Demonstrating Synergy with BCL-2 Family Inhibitors in AML at the 2024 ASH Annual Meeting
December 10, 2024 08:00 ET
|
Remedy Plan Therapeutics
Remedy Plan Therapeutics Showcases at 2024 ASH Annual Meeting, Synergy Between RPT1G and Venetoclax
Chronic Myelomonocytic Leukaemia Drug Pipeline Research 2024
July 01, 2024 09:04 ET
|
Research and Markets
Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myelomonocytic Leukaemia - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Chronic...
Innovative Developments in Acute Lymphocytic Leukemia (ALL) Treatments Global Pipeline Report 2024
June 20, 2024 05:58 ET
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Acute Lymphocytic Leukemia (ALL) - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.Global insights into the...
Leukemia Therapeutics Market: Robust Growth Expected with Innovative CAR-T Treatments
January 23, 2024 15:23 ET
|
Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive research on...
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
October 30, 2023 09:15 ET
|
Aptose Biosciences, Inc.
Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients
Global Leukemia Therapeutics Market Report 2023: Rising Prevalence of Leukemia is Driving Growth
May 08, 2023 05:33 ET
|
Research and Markets
Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
Leukemia Therapeutics Global Market Report 2023: Rises in Product Approvals and Increasing Diagnosis Awareness Drives Growth
May 02, 2023 07:33 ET
|
Research and Markets
Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Market by Type, Drug Class, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been...
Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia
April 12, 2022 07:00 ET
|
Cyclacel
-New Preclinical Data Highlight Fadraciclib’s Apoptosis Enabling Mechanism in Leukemia- -Remarkable Synergy Observed with Venetoclax, esp. in Resistant CLL cells with 17p Deletion- BERKELEY HEIGHTS,...